- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines | 218 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - August 4, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Helix Nanotechnologies Inc. ("HelixNano"), a Boston-based biotech company focused... ► Artikel lesen | |
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| Mo | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.07. | Medicus Pharma Ltd. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.07. | Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders | 250 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - July 23, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the voting results of the Company's annual and... ► Artikel lesen | |
| 21.07. | Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025 | 259 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - July 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the scheduling of the Fireside chat of Dr. Raza... ► Artikel lesen | |
| 14.07. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA) | 254 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - July 8, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive package to the United... ► Artikel lesen | |
| 04.07. | Medicus Pharma: Pflaster gegen Hautkrebs - ein Investment wert? | 566 | sharedeals.de | Eine hierzulande wohl ziemlich unbekannte Aktie ist die von Medicus Pharma. Das Unternehmen aus Kanada ist seit Ende letzten Jahres auch an der US-Nasdaq gelistet und hat Großes vor. Wenn der Plan aufgeht... ► Artikel lesen | |
| 30.06. | Medicus Pharma Ltd. - 8-K, Current Report | - | SEC Filings | ||
| 30.06. | Medicus Pharma to acquire Antev | 5 | Seeking Alpha | ||
| 30.06. | Medicus Pharma Ltd.: Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK | 348 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - June 30, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Antev Ltd. ("Antev"), a UK-based clinical-stage drug development company, announced... ► Artikel lesen | |
| 30.06. | XFRA DELETION OF INSTRUMENTS FROM XETRA - 30.06.2025 | 126 | Xetra Newsboard | The following instruments on XETRA do have their last trading day on 30.06.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 30.06.2025ISIN NameCA58471K2020 MEDICUS PHARMA LTD.DE000HLB5782... ► Artikel lesen | |
| 23.06. | Medicus Pharma appoints Andrew Smith as chief operating officer | 2 | Investing.com | ||
| 23.06. | Medicus Pharma ernennt Andrew Smith zum Chief Operating Officer | 2 | Investing.com Deutsch | ||
| 23.06. | Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer | 267 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - June 23, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the appointment of Andrew Smith as Chief Operating... ► Artikel lesen | |
| 20.06. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.06. | Medicus Pharma Ltd. to Present at 2025 Bio International Convention | 253 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - June 12, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the schedule of the presentation of Dr. Raza Bokhari... ► Artikel lesen | |
| 09.06. | Medicus Pharma advances cancer patch for horses | 2 | Investing.com | ||
| 09.06. | Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses | 266 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - June 9, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive product development... ► Artikel lesen | |
| 02.06. | Medicus Pharma Ltd. - 8-K, Current Report | - | SEC Filings |
1 2 3 4 Weiter >>
75 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,105 | -0,07 % | Ihre wichtigsten Termine: Frische Zahlen von: Cummins, AMD, Snap, Pfizer, Infineon, Continental und DHL | © Foto: picture alliance/pressefoto_korb/Micha Korb - pressefoto_korb picture alliance/pressefoto_korb/Micha KorbGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im... ► Artikel lesen | |
| GILEAD SCIENCES | 102,64 | +0,06 % | Starke Zahlen, angehobener Ausblick und günstige Bewertung: Gilead Sciences weiß zu überzeugen! | Das US-Biotechunternehmen Gilead Sciences hat am Donnerstagabend starke Zahlen vorgelegt. Die Aktie bietet Anlegerinnen und Anlegern ein attraktives Gesamtpaket. Diese Quartalssaison ist für Biotechwerte... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 313,15 | -0,49 % | Studie eingestellt: Vertex Pharmaceuticals crasht trotz starker Quartalszahlen! | Die Aktie von Vertex Pharmaceuticals steht am Dienstag vor empfindlichen Verlusten. Starke Quartalszahlen werden von einer eingestellten Studie überschattet. Vertex Pharmaceuticals: Einer der konstantesten... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 8,772 | -0,14 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments | - Completed Phase 3 enrollment for DURAVYU in wet AMD with over 800 patients enrolled and randomized - - LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician... ► Artikel lesen | |
| ROCKET LAB | 38,600 | +0,52 % | Söllner: 50-%-Crash? Risiko AMD für Nvidia! Star Wars: Xiaomi, VW, Bitcoin, EA, CoBa, Rocket Lab | Florian Söllner, leitender Redakteur bei DER AKTIONÄR, blickt jede Woche auf die spannendsten Entwicklungen im Tech-Sektor. Heute geht es um folgende Werte: Rocket Lab, Kawasaki, Frequentis, ABB, Fanuc... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 5,400 | 0,00 % | Astria Therapeutics licenses navenibart rights to Kaken for HAE | ||
| OPKO HEALTH | 1,093 | +2,23 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 125,00 | +0,81 % | Ligand Pharmaceuticals: Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance | Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million)... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 95,50 | -0,21 % | Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma | Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adultsAccelerated approval based on an overall response... ► Artikel lesen | |
| ROYALTY PHARMA | 32,320 | +0,12 % | Royalty Pharma Plc Q2 Income Retreats | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) released a profit for second quarter that Drops, from the same period last yearThe company's earnings came in at $30.17 million, or $0.07 per... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 16,840 | -1,26 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors | CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of... ► Artikel lesen | |
| TG THERAPEUTICS | 22,995 | +0,24 % | TG Therapeutics, Inc.: TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance | Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 7,400 | +1,37 % | Corbus Pharma's Q2 Net Loss Widens | ||
| CATALENT | 59,93 | 0,00 % | BMO Capital lowers Scholar Rock stock price target to $45 on Novo Catalent concerns | ||
| TALPHERA | 0,340 | -1,31 % | Talphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update | Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025... ► Artikel lesen |
MEDICUS PHARMA LTD gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,210 (-9,63 %) liegt der Kurs bei 1,970 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.